Oxford-based Owen Mumford appoints new Director of Research & Development
Owen Mumford, a global industry leader in medical device design and manufacturing based in Oxford, has appointed Professor Andrew Lewis as Research & Development Director as part of its continued investment in innovation.
Andrew is a Chartered Chemist and Fellow of The Royal Academy of Engineering as well as a Fellow of the Academy of Pharmaceutical Sciences. He is also a Visiting Professor of Biomaterials and Drug Delivery at the University of Brighton and has been recognised by the Pharmaceutical Society with an Excellence and Innovation Award.
Andrew has extensive experience within the technical and scientific field across a number of leading pharmaceutical and medical devices companies. Most recently, he led a global cross-platform team of technical heads as Vice President of R&D with Innovation at Boston Scientific, where he spearheaded multiple scientific collaborations with several highly-respected institutions including Edinburgh University.
Jarl Severn, Managing Director at Owen Mumford, says Andrew’s experience and knowledge will further support the company in ensuring innovation and scientific rigour are central to its R&D strategies:
“Andrew is extremely well-respected in the science and medical community as a regular conference speaker and contributor to scientific publications. He is known for developing R&D strategies and applying the latest management thinking to innovation pipelines focused on drug-device combinations. This innovative thinking will make him an invaluable asset to our company.”
Andrew joins Owen Mumford at an exciting time: “As a UK manufacturer, the company is launching a number of new devices designed to make the lives of health care professionals and patients safer and easier,” he says. “I’m looking forward to supporting and furthering Owen Mumford’s commitment to these critical safety goals.”
More in Manufacturing
Unipart announces financial results for the year ended 31 December 2023
Unipart delivers strong growth and revenues exceed £1bn
Intertronics acquires Dyne Testing
~ Surface measurement business now a wholly owned subsidiary of Intertronics ~
Owen Mumford acquires Empelvic
Owen Mumford Expands Pelvic Health Portfolio with Acquisition of Empelvic
From this author
Owen Mumford’s Near-Term and Net-Zero targets approved by the SBTi
Owen Mumford, a leader in the medical device industry and certified B Corp, has announced that the Science Based Targets initiative (SBTi) has approved its near-term science-based emissions reduction target. The medical device manufacturer has also committed to set long-term emissions reduction targets with the SBTi in line with reaching net-zero by 2045 – 5 years ahead of the UK’s net-zero target.
Owen Mumford acquires Empelvic
Owen Mumford Expands Pelvic Health Portfolio with Acquisition of Empelvic
Owen Mumford partners with Duopharma Biotech to distribute medical devices
Partnership with leading pharmaceutical company will supply diabetes and eye care devices in the Malaysia and Brunei markets